Beginning July 2026, certain Medicare beneficiaries will gain access to GLP-1 medications through a flat monthly fee. This temporary program is scheduled to last until the end of 2027. Although the launch is approaching, operational details remain unclear.
Program Outline
The Medicare GLP-1 Bridge, described by the Centers for Medicare and Medicaid Services (CMS) as a “time-limited demonstration,” is set to run from July 1, 2026, to December 31, 2027. Announced in December, Medicare Part D enrollees can access GLP-1 medications for a $50 monthly copay. The program primarily targets weight management, aligning with federal law prohibiting Medicare from covering weight loss medications. The Obesity Care Advocacy Network (OCAN) praised this initiative as a significant step against the obesity epidemic.
Operational Concerns
Queries regarding administration and costs persist. Bob Herman from Stat News reported that CMS has not provided information on costs, and inquiries from various sources also remain unanswered.
How It Works
According to CMS, beneficiaries need a prescription from their doctor, which requires a medical provider to submit a prior authorization request for eligible GLP-1 medications. Covered medications include Wegovy, Zepbound, and Foundayo. A central processor, Bridge PCN, handles prescriptions routed from pharmacies. Aurelia Chaudhury from CMS noted that prospective prior authorizations occur at the time of prescribing. Unapproved claims will be rejected, requiring a prior authorization form where physicians verify the absence of specific conditions in patients. The monthly copay does not contribute to deductibles or maximum out-of-pocket expenses.
Eligibility Criteria
Beneficiaries must enroll in a standalone prescription drug plan or Medicare Advantage coordinated care plan. Special Needs Plans, employer group plans, and Tricare For Life, among others, are eligible if combined with Part D. Dual enrollees in Medicare and Medicaid may qualify. Eligibility involves having a BMI of 27 or higher and a diagnosis of prediabetes, prior heart events, or peripheral artery disease. Those with a BMI of 30 or greater require diagnoses of additional conditions like heart failure, hypertension, or chronic kidney disease.
Regulatory Concerns
The program operates outside typical Medicare boundaries, leading to potential fraud concerns. Christopher Frisina, healthcare regulatory counsel, warned about misuse through telehealth prescriptions, as Medicare demands stringent business practices. Despite CMS implementing checks with detailed authorization forms requiring provider-pharmacy coordination, fraud remains a risk.
Cost estimates and enrollment projections from CMS are not publicly available. The demonstration runs independently of normal Part D benefit structures, affecting cost-sharing and payment flows.
Leave a Reply